A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide

There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration‐resistant prostate cancer (CRPC).

[1]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[2]  F. Saad,et al.  Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[3]  A. Wyatt,et al.  Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. , 2019, JCO precision oncology.

[4]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[5]  P. Nelson,et al.  Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer , 2018, The Journal of clinical investigation.

[6]  G. Sonpavde,et al.  Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[8]  David S. K. Lu,et al.  Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer , 2018, JAMA oncology.

[9]  Joshua M. Stuart,et al.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer , 2018, Cell.

[10]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[11]  D. Amadori,et al.  Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  F. Saad,et al.  Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. , 2017, European urology.

[13]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[14]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[15]  Tomasz Burzykowski,et al.  Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Scher,et al.  Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate , 2015, Clinical Cancer Research.

[17]  F. Demichelis,et al.  Tumor clone dynamics in lethal prostate cancer , 2014, Science Translational Medicine.

[18]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[19]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[20]  H. Scher,et al.  TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. , 2011, European urology.

[21]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[22]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[23]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[24]  D. Dearnaley,et al.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.

[25]  Xiaoyu Jia,et al.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. , 2009, The Lancet. Oncology.

[26]  S. Dhanasekaran,et al.  ETS rearrangements and prostate cancer initiation , 2009, Nature.

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[28]  M. Ittmann,et al.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. , 2008, Cancer research.

[29]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[31]  Debashis Ghosh,et al.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.

[32]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[33]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[34]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[35]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.